Strategic Appointment in Biotechnology with Birgitte Volck
OMass Therapeutics, a prominent player in the biotechnology sector, has announced a pivotal addition to its Board of Directors. Birgitte Volck, an accomplished MD and PhD who has accumulated over 25 years of expertise in the global healthcare arena, joins as a non-executive director.
Birgitte Volck's Extensive Experience
Dr. Volck's career is distinguished by her leadership in research and development as well as her innovative contributions to the field of precision medicine, particularly in the domain of rare diseases. She has had a significant impact on Boards of various high-profile biotech firms, such as Soleno Therapeutics and Nykode Therapeutics, enhancing strategic direction and oversight.
Key Previous Roles
Throughout her illustrious career, Dr. Volck has held critical positions that demonstrate her extensive knowledge and leadership. In her previous role at Ascendis Pharma as Executive Vice President and Interim Chief Medical Officer, she successfully directed clinical development and regulatory affairs, focusing on rare disease strategies. Her tenure at Avrobio Inc. as President of R&D showcases her ability to oversee complex gene therapy programs.
Contributions to Rare Disease Therapeutics
Dr. Volck's contributions extend to her work at GSK, where she was pivotal in shaping the rare disease portfolio by leveraging both internal and external partnerships to develop innovative therapies. Her experience doesn't stop there; she has also spearheaded advancements in specialty care treatments at other companies such as Sobi, Amgen, and Genzyme.
OMass Therapeutics’ Vision
Jim Geraghty, Chairman of the Board at OMass Therapeutics, emphasized the value of Dr. Volck's appointment, noting her extensive experience in drug development across multiple indications. This strategic move is aligned with OMass' goals as the company evolves into a clinical-stage organization.
Dr. Volck’s Commitment to OMass
Upon her joining, Dr. Volck expressed her admiration for OMass Therapeutics, highlighting the company’s innovative drug discovery approach focused on protein interactions within their native environments. Her passion for developing pioneering medicines resonates with OMass’ mission to enter the clinical arena with its leading compounds like the MC2 antagonist, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.
Introduction to OMass Therapeutics
Headquartered in Oxford, OMass Therapeutics has established itself by utilizing its unique OdyssION™ platform, which combines next-generation native mass spectrometry and advanced biochemistry techniques. This innovative approach allows for a distinct understanding of drug-target interactions outside conventional cellular complexities, thus offering high fidelity cell system responses.
Investment and Growth
OMass Therapeutics has demonstrated substantial growth by securing over $160 million from an esteemed international investor alliance, reinforcing its commitment to developing game-changing therapies for rare diseases and immunological disorders.
Research and Development Focus
The company is currently advancing a small molecule therapeutic pipeline, standing out with its MC2 receptor antagonist program designed specifically for the treatment of congenital adrenal hyperplasia (CAH) and Cushing's Syndrome. This initiative seeks to enhance the efficacy of its treatments by ensuring sustained receptor interaction even in fluctuating hormonal environments.
Frequently Asked Questions
What does Birgitte Volck's appointment mean for OMass Therapeutics?
Her extensive experience in drug development and leadership will guide OMass as it advances into clinical stages and strengthens its strategic initiatives.
What is the focus of OMass Therapeutics?
OMass focuses on discovering therapies for rare diseases and immunological disorders using its unique drug discovery platform.
How has OMass Therapeutics been funded?
The company has raised over $160 million from a top-tier investor syndicate, supporting its research and development efforts.
What is the significance of the MC2 receptor antagonist?
This innovative therapy targets congenital adrenal hyperplasia and Cushing’s syndrome, aiming to improve treatment efficacy and patient outcomes.
Where is OMass Therapeutics headquartered?
OMass Therapeutics is based in Oxford, United Kingdom, where it conducts its research and development activities.
